主权项 |
1. A method of determining whether a patient is likely to respond to treatment with a VEGF antagonist, the method comprising:
(a) detecting expression of at least one of the following genes, DLL4, angiopoietin 2 (Angpt2), NOS2, Factor V, Factor VIII (AHF), EGFL7, EFNA3, PGF, ANGPTL1, SELP, Cox2, Fibronectin (FN_EIIIB), ESM1, and stromal derived growth factor (SDF1), in a biological sample obtained from the patient prior to any administration of a VEGF antagonist to the patient; (b) comparing the expression level of the at least one gene to a reference expression level of the at least one gene, wherein a change in the level of expression of the at least one gene in the patient sample relative to the reference level identifies a patient who is likely to respond to treatment with a VEGF antagonist; and (c) informing the patient that they have an increased likelihood of being responsive to treatment with a VEGF antagonist. |